Literature DB >> 27976853

Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome.

Hao-Chi Hsu1, Pradeep K Singh, Hao Fan, Rong Wang2, George Sukenick2, Carl Nathan, Gang Lin, Huilin Li1.   

Abstract

The Mycobacterium tuberculosis (Mtb) 20S proteasome is vital for the pathogen to survive under nitrosative stress in vitro and to persist in mice. To qualify for drug development, inhibitors targeting Mtb 20S must spare both the human constitutive proteasome (c-20S) and immunoproteasome (i-20S). We recently reported members of a family of noncovalently binding dipeptide proteasome inhibitors that are highly potent and selective for Mtb 20S over human c-20S and i-20S. To understand the structural basis of their potency and selectivity, we have studied the structure-activity relationship of six derivatives and solved their cocrystal structures with Mtb 20S. The dipeptide inhibitors form an antiparallel β-strand with the active site β-strands. Selectivity is conferred by several features of Mtb 20S relative to its mouse counterparts, including a larger S1 pocket, additional hydrogen bonds in the S3 pocket, and hydrophobic interactions in the S4 pocket. Serine-20 and glutamine-22 of Mtb 20S interact with the dipeptides and confer Mtb-specific inhibition over c-20S and i-20S. The Mtb 20S and mammalian i-20S have a serine-27 that interacts strongly with the dipeptides, potentially explaining the higher inhibitory activity of the dipeptides toward i-20S over c-20S. This detailed structural knowledge will aid in optimizing the dipeptides as anti-tuberculosis drugs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27976853      PMCID: PMC5745808          DOI: 10.1021/acs.biochem.6b01107

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  35 in total

1.  20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A.

Authors:  Michael Groll; Nerea Gallastegui; Xavier Maréchal; Virginie Le Ravalec; Nicolas Basse; Nicolas Richy; Emilie Genin; Robert Huber; Luis Moroder; Joëlle Vidal; Michèle Reboud-Ravaux
Journal:  ChemMedChem       Date:  2010-10-04       Impact factor: 3.466

2.  The mycobacterial Mpa-proteasome unfolds and degrades pupylated substrates by engaging Pup's N-terminus.

Authors:  Frank Striebel; Moritz Hunkeler; Heike Summer; Eilika Weber-Ban
Journal:  EMBO J       Date:  2010-03-04       Impact factor: 11.598

3.  Crystal structure of the human 20S proteasome in complex with carfilzomib.

Authors:  Wayne Harshbarger; Chase Miller; Chandler Diedrich; James Sacchettini
Journal:  Structure       Date:  2015-01-15       Impact factor: 5.006

4.  Structural Analysis of the Bacterial Proteasome Activator Bpa in Complex with the 20S Proteasome.

Authors:  Marcel Bolten; Cyrille L Delley; Marc Leibundgut; Daniel Boehringer; Nenad Ban; Eilika Weber-Ban
Journal:  Structure       Date:  2016-11-10       Impact factor: 5.006

5.  Identification of substrates of the Mycobacterium tuberculosis proteasome.

Authors:  Michael J Pearce; Pooja Arora; Richard A Festa; Susan M Butler-Wu; Rajesh S Gokhale; K Heran Darwin
Journal:  EMBO J       Date:  2006-11-02       Impact factor: 11.598

6.  Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates.

Authors:  Gang Lin; Christopher Tsu; Lawrence Dick; Xi K Zhou; Carl Nathan
Journal:  J Biol Chem       Date:  2008-10-01       Impact factor: 5.157

Review 7.  A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis.

Authors:  Carl Nathan; Ben Gold; Gang Lin; Melanie Stegman; Luiz Pedro Sorio de Carvalho; Omar Vandal; Aditya Venugopal; Ruslana Bryk
Journal:  Tuberculosis (Edinb)       Date:  2008-08       Impact factor: 3.131

8.  N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets.

Authors:  Gang Lin; Tamutenda Chidawanyika; Christopher Tsu; Thulasi Warrier; Julien Vaubourgeix; Christopher Blackburn; Kenneth Gigstad; Michael Sintchak; Lawrence Dick; Carl Nathan
Journal:  J Am Chem Soc       Date:  2013-06-25       Impact factor: 15.419

9.  Towards automated crystallographic structure refinement with phenix.refine.

Authors:  Pavel V Afonine; Ralf W Grosse-Kunstleve; Nathaniel Echols; Jeffrey J Headd; Nigel W Moriarty; Marat Mustyakimov; Thomas C Terwilliger; Alexandre Urzhumtsev; Peter H Zwart; Paul D Adams
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2012-03-16

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  7 in total

1.  Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.

Authors:  Wenhu Zhan; Hao-Chi Hsu; Trevor Morgan; Tierra Ouellette; Kristin Burns-Huang; Ryoma Hara; Adrian G Wright; Toshihiro Imaeda; Rei Okamoto; Kenjiro Sato; Mayako Michino; Manoj Ramjee; Kazuyoshi Aso; Peter T Meinke; Michael Foley; Carl F Nathan; Huilin Li; Gang Lin
Journal:  J Med Chem       Date:  2019-10-15       Impact factor: 7.446

2.  Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.

Authors:  Hao Zhang; Hao-Chi Hsu; Shoshanna C Kahne; Ryoma Hara; Wenhu Zhan; Xiuju Jiang; Kristin Burns-Huang; Tierra Ouellette; Toshihiro Imaeda; Rei Okamoto; Masanori Kawasaki; Mayako Michino; Tzu-Tshin Wong; Akinori Toita; Takafumi Yukawa; Francesca Moraca; Jeremie Vendome; Priya Saha; Kenjiro Sato; Kazuyoshi Aso; John Ginn; Peter T Meinke; Michael Foley; Carl F Nathan; K Heran Darwin; Huilin Li; Gang Lin
Journal:  J Med Chem       Date:  2021-05-05       Impact factor: 7.446

3.  Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides.

Authors:  Wenhu Zhan; Pradeep K Singh; Yi Ban; Xiaoping Qing; Marie Dominique Ah Kioon; Hao Fan; Quanju Zhao; Rong Wang; George Sukenick; Jane Salmon; J David Warren; Xiaojing Ma; Franck J Barrat; Carl F Nathan; Gang Lin
Journal:  J Med Chem       Date:  2020-10-23       Impact factor: 8.039

Review 4.  Targeting the Proteostasis Network for Mycobacterial Drug Discovery.

Authors:  Tania J Lupoli; Julien Vaubourgeix; Kristin Burns-Huang; Ben Gold
Journal:  ACS Infect Dis       Date:  2018-03-02       Impact factor: 5.084

5.  Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance.

Authors:  Laura A Kirkman; Wenhu Zhan; Joseph Visone; Alexis Dziedziech; Pradeep K Singh; Hao Fan; Xinran Tong; Igor Bruzual; Ryoma Hara; Masanori Kawasaki; Toshihiro Imaeda; Rei Okamoto; Kenjiro Sato; Mayako Michino; Elena Fernandez Alvaro; Liselle F Guiang; Laura Sanz; Daniel J Mota; Kavitha Govindasamy; Rong Wang; Yan Ling; Patrick K Tumwebaze; George Sukenick; Lei Shi; Jeremie Vendome; Purnima Bhanot; Philip J Rosenthal; Kazuyoshi Aso; Michael A Foley; Roland A Cooper; Bjorn Kafsack; J Stone Doggett; Carl F Nathan; Gang Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-02       Impact factor: 11.205

6.  Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome.

Authors:  Kaja Rožman; Evan M Alexander; Eva Ogorevc; Krištof Bozovičar; Izidor Sosič; Courtney C Aldrich; Stanislav Gobec
Journal:  Molecules       Date:  2020-03-12       Impact factor: 4.411

Review 7.  Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.

Authors:  Yu Cao; Huajian Zhu; Ruoyu He; Limin Kong; Jiaan Shao; Rangxiao Zhuang; Jianjun Xi; Jiankang Zhang
Journal:  Drug Des Devel Ther       Date:  2020-10-19       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.